Verisante Technology, Inc.
TSX VENTURE : VRS
OTCQX : VRSEF

Verisante Technology, Inc.

July 29, 2014 10:00 ET

Verisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 29, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, is pleased to welcome Dr. Kenneth Beer, MD, PA and Dr. Wm. Philip Werschler, MD, FAAD, FAACS, onto the Company's Clinical Advisory Board.

"Both Dr. Beer and Dr. Werschler have extensive experience assisting companies with setting up scientific advisory boards, advising with clinical studies and navigating the medical device regulatory regime in the United States," said Thomas Braun, President & CEO. "We are fortunate to have two experts in their field join our Advisory Board and look forward to working closely together to further the objectives of Verisante."

Dr. Beer is a Florida based board certified dermatologist and dermatopathologist who has served the Palm Beach, Broward and Martin area for over 15 years, with offices in West Palm Beach and Jupiter. He is also a Fellow of the American Academy of Dermatology, a Fellow of the American Society of Dermatologic Surgery, volunteer assistant professor at the University of Miami, Consulting Associate with the Department of Medicine at Duke University and a member of the Thoracic Cancer Society.

"Verisante's technology certainly has the potential to make a significant impact on the clinical setting and patient outcomes when it is introduced into the United Stated," said Dr. Beer. "Not only can Aura™ meet the need for dermatologists and physicians' with a skin specialty to have better tools to assist in diagnosing skin cancer, but as member of the Thoracic Cancer Society, I see the applications for the Core™ technology to be highly disruptive in the field."

Dr. Werschler, also a board certified dermatologist and skin cancer surgeon, is an internationally recognized expert in both medical and cosmetic dermatology/aesthetic surgery, and in this capacity he has been honored to serve as a FDA investigator for clinical trials of both drugs and devices throughout his career. Today, nearly all of the FDA approved aesthetic injectable dermal fillers and toxins were tested in his research center, Premier Clinical Research, in Spokane, WA. Dr. Werschler also has extensive experience in the conduct of investigative clinical trials for both precancerous lesions and skin cancers.

"I have been following Aura™ with intense interest for several years now, and look forward to assisting in any investigative clinical trials that might be necessary to bring this exciting technology to the United States. The opportunity of non-invasive diagnosis for skin cancer is potentially a complete game changer in the clinical practice of dermatology and cutaneous oncology. The Aura™ combines emergent technology with patient friendly evaluation of suspicious skin lesions for both melanoma and non-melanoma skin cancers. Any tool that can help a doctor become better at assessing skin cancer can only be a benefit to both doctors and patients", said Dr. Werschler.

About Dr. Kenneth Beer, MD, PA

Dr. Kenneth R. Beer, MD PA is board certified in both dermatology and dermatopathology, the microscopic study of the skin. He is one of the few cosmetic and surgical dermatologists to be credentialed in both specialties. Dr. Beer completed his residency in dermatology and fellowship in dermatopathology at The University of Chicago. He is a voluntary assistant professor at the University of Miami and a consulting associate in the Department of Medicine at Duke University.

Dr. Beer has authored numerous publications including several scientific articles and chapters in textbooks of Cosmetic Surgery and Dermatology. Among the publications Dr. Beer has published are articles comparing various topical creams with Botox, different types of fillers used to treat nasolabial creases and a host of others that have advanced the field of dermatology. He is renowned as one of the country's top experts in Botox and has published extensively in cosmetic dermatology journals, including "Cosmetic Dermatology," "Dermatologic Surgery" and is the author of the monthly "Cosmetic Clinic" for dermatologists that appears in "Skin and Aging" magazine. By combining his dermatology and dermatopathology expertise, Dr. Beer has become a leader in skin cancer surgery and reconstruction as well as cosmetic dermatology.

About Dr. Wm. Philip Werschler, MD, FAAD, FAACS

Dr. Wm. Philip Werschler MD is the founding member of Spokane Dermatology Clinic and Werschler Aesthetics. Dr. Werschler has been an active teaching member of the University of Washington faculty for over 20 years, where he serves as a Clinical Professor in Medicine/Dermatology. A graduate of the George Washington University, School of Medicine, Washington, D.C. He is affiliated with several professional societies, including a full fellow of the American Academy of Dermatology, the American Academy of Cosmetic Surgery, American Society for Dermatological Surgery and the American Society for Mohs Surgery.

Dr. Werschler has contributed extensively to the dermatologic literature and is the founding aesthetic Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, a leading PubMed listed specialty journal. Dr. Werschler is also the Editor-in-Chief of Cosmetic Dermatology, the specialty's original journal for cosmetic and aesthetic dermatology. He is on the editorial boards of multiple scholarly journals including Skin and Aging, Cutis, and the Journal of Drugs in Dermatology. Dr. Werschler lectures both nationally and internationally on advances in the field of dermatology, aesthetic medicine and surgery.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact Information